NCT01800903

Brief Summary

The aim of the study is to evaluate safety and performance of a new catheter coating,compared to the current SpeediCath coating.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2013

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2013

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

February 22, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 28, 2013

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2013

Completed
12 months until next milestone

Results Posted

Study results publicly available

March 14, 2014

Completed
Last Updated

September 10, 2020

Status Verified

August 1, 2020

Enrollment Period

2 months

First QC Date

February 22, 2013

Results QC Date

November 29, 2013

Last Update Submit

August 26, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Overall Discomfort During Catheterization

    Evaluated by the subject on a 10 cm Visual Analog Scale (VAS), where 0 cm is no discomfort and 10 cm is the worst possible discomfort.

    1 day

Study Arms (6)

Sequence 1

ACTIVE COMPARATOR

SpeediCath catheter then ZN-D catheter then ZN-C catheter

Device: ZN-D catheterDevice: ZN-C catheterDevice: SpeediCath catheter

Sequence 2

EXPERIMENTAL

SpeediCath catheter then ZN-C catheter then ZN-D catheter

Device: ZN-D catheterDevice: ZN-C catheterDevice: SpeediCath catheter

Sequence 3

EXPERIMENTAL

ZN-D catheter then SpeediCath catheter then ZN-C catheter

Device: ZN-D catheterDevice: ZN-C catheterDevice: SpeediCath catheter

Sequence 4

EXPERIMENTAL

ZN-D catheter then ZN-C catheter then SpeediCath catheter

Device: ZN-D catheterDevice: ZN-C catheterDevice: SpeediCath catheter

Sequence 5

EXPERIMENTAL

ZN-C catheter then SpeediCath catheter then ZN-D catheter

Device: ZN-D catheterDevice: ZN-C catheterDevice: SpeediCath catheter

Sequence 6

EXPERIMENTAL

ZN-C catheter then ZN-D catheter then SpeediCath catheter

Device: ZN-D catheterDevice: ZN-C catheterDevice: SpeediCath catheter

Interventions

ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.

Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6

ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.

Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6

The Speedicath cathere is CE-marked and commercially available.

Sequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Have given written informed consent and signed letter of authority
  • Be at least 18 years of age and have full legal capacity
  • Be a male
  • Willing to refrain from using analgetics up to 24 hours prior to catheterization visits

You may not qualify if:

  • Abnormalities, diseases or surgical procedures performed in the lower urinary tract
  • Symptoms of urinary tract infections (at least one of the following: frequent urination, stinging or pain at urination)
  • Known hypersensitivity toward any of the test products -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Urology

Copenhagen, 2100, Denmark

Location

Results Point of Contact

Title
Trine Møller Senior Clinical Manager
Organization
Coloplast A/S

Study Officials

  • Per Bagi, MD, PhD

    Department of Urology, Rigshospitalet Denmark

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 22, 2013

First Posted

February 28, 2013

Study Start

February 1, 2013

Primary Completion

April 1, 2013

Study Completion

April 1, 2013

Last Updated

September 10, 2020

Results First Posted

March 14, 2014

Record last verified: 2020-08

Locations